中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

7 records (took 0.02 seconds)

    CD28 T CELL CULTURES, COMPOSITIONS, AND METHODS OF USING THEREOF
    3.
    发明申请
    CD28 T CELL CULTURES, COMPOSITIONS, AND METHODS OF USING THEREOF 审中-公开

    公开(公告)号：US20200297768A1

    公开(公告)日：2020-09-24

    申请号：US16823987

    申请日：2020-03-19

    Applicant: IMMATICS US, INC.

    Inventor： Amir ALPERT ,  Mamta KALRA

    IPC: A61K35/17 ,  A61P35/00 ,  C12N15/86 ,  C12N5/0783

    Abstract: A method for producing T cells with improved efficacy for adoptive immunotherapy includes obtaining a population of CD8+ T cells from a patient or a donor, determining a % of CD28+CD8+ T cells in the obtained population, activating the determined population with anti-CD3 antibody and anti-CD28 antibody, provided that the determined population comprises at least 50% of CD28+CD8+ T cells, or activating the determined population with anti-CD3 antibody in the absence of anti-CD28 antibody, provided that the determined population comprises less than 50% of CD28+CD8+ T cells, transducing the activated population with a viral vector, and expanding the transduced population, in which the transducing and the expanding are carried out in the presence of at least one cytokine.

    CD28 T CELL CULTURES, COMPOSITIONS, AND METHODS OF USING THEREOF
    4.
    发明申请
    CD28 T CELL CULTURES, COMPOSITIONS, AND METHODS OF USING THEREOF 有权

    公开(公告)号：US20250019655A1

    公开(公告)日：2025-01-16

    申请号：US18893532

    申请日：2024-09-23

    Applicant: Immatics US, Inc.

    Inventor： Amir ALPERT ,  Mamta KALRA

    IPC: C12N5/0783 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28 ,  C12N15/86

    Abstract: A method for producing T cells with improved efficacy for adoptive immunotherapy includes obtaining a population of CD8+ T cells from a patient or a donor, determining a % of CD28+ CD8+ T cells in the obtained population, activating the determined population with anti-CD3 antibody and anti-CD28 antibody, provided that the determined population comprises at least 50% of CD28+ CD8+ T cells, or activating the determined population with anti-CD3 antibody in the absence of anti-CD28 antibody, provided that the determined population comprises less than 50% of CD28+ CD8+ T cells, transducing the activated population with a viral vector, and expanding the transduced population, in which the transducing and the expanding are carried out in the presence of at least one cytokine.

    METHODS FOR GENERATING CELL SPHEROIDS
    5.
    发明公开
    METHODS FOR GENERATING CELL SPHEROIDS 审中-公开

    公开(公告)号：US20230142468A1

    公开(公告)日：2023-05-11

    申请号：US18053165

    申请日：2022-11-07

    Applicant: Immatics US, Inc. ,  Immatics Biotechnologies GmbH

    Inventor： Inbar ALFAGUTER ,  Sara YOUSEF ,  Kathy-Ann SECKER ,  Amir ALPERT ,  Juliane PALMER ,  Maike JAWORSKI

    IPC: C12N5/00

    CPC classification number: C12N5/0062 ,  C12N2533/90 ,  C12N2513/00

    Abstract: The present disclosure relates to improved methods for generating multicellular spheroids. In embodiments, an improved method may comprise (a) providing cells capable of spheroid formation; (b) centrifuging the cells; (c) adding extracellular matrix to the cells of (b) to produce a cell suspension comprising a desired concentration of extracellular matrix; and (d) allowing at least one spheroid to form; wherein (b) is performed before (c). In embodiments, cells may be seeded on a tissue culture apparatus before extracellular matrix is added to the cells. In embodiments, spheroids may be characterized, analyzed, challenged, otherwise tested, or a combination thereof. In embodiments, cells may be seeded in a volume of media that is a fraction of a volume of media that is desired for characterization, analysis, challenging, otherwise testing, or a combination thereof.

    METHOD OF ENHANCING PERSISTENCE OF ADOPTIVELY INFUSED T CELLS
    6.
    发明申请
    METHOD OF ENHANCING PERSISTENCE OF ADOPTIVELY INFUSED T CELLS 有权

    公开(公告)号：US20210017493A1

    公开(公告)日：2021-01-21

    申请号：US17062234

    申请日：2020-10-02

    Applicant: Immatics US, Inc.

    Inventor： Amir ALPERT

    IPC: C12N5/0783 ,  A61P35/00 ,  A61K35/17

    Abstract: The present disclosure provides for methods of improving the efficacy of T cells. In an aspect, the disclosure further provides for methods of enhancing the persistence of T cells for adoptive cell transfer or therapy (ACT). Cytokine sensitivity assays (CSA) and associated methodology capable of predicting the persistence of adoptively infused T Cells are further provided for by way of the instant disclosure. The disclosure also provides for methods of treating cancer in a subject in need thereof as well as T cells populations produced by methods described herein.

Patent Agency Ranking